Liu Yuan, Holmes Christina
Department of Chemical and Biomedical Engineering, Florida A&M University-Florida State University College of Engineering, Tallhassee, FL, United States.
Front Cell Dev Biol. 2021 Feb 26;9:648098. doi: 10.3389/fcell.2021.648098. eCollection 2021.
Mesenchymal stem cell (MSC)-based therapies have demonstrated tissue repair and regeneration capacity in various preclinical models. These therapeutic effects have recently been largely attributed to the paracrine effects of the MSC secretome, including proteins and extracellular vesicles (EVs). EVs are cell-secreted nano-sized vesicles with lipid bilayer membranes that facilitate cell-cell signaling. Treatments based on MSC-derived EVs are beginning to be explored as an alternative to MSC transplantation-based therapies. However, it remains to be determined which MSC source produces EVs with the greatest therapeutic potential. This review compares the tissue regeneration capacity of EVs isolated from the two most common clinical sources of adult MSCs, bone marrow and adipose tissue, with a particular focus on their angiogenic, osteogenic, and immunomodulatory potentials. Other important issues in the development of MSC-derived EV based therapies are also discussed.
基于间充质干细胞(MSC)的疗法已在各种临床前模型中展现出组织修复和再生能力。这些治疗效果近来很大程度上归因于MSC分泌组的旁分泌作用,包括蛋白质和细胞外囊泡(EVs)。EVs是细胞分泌的具有脂质双分子层膜的纳米级囊泡,有助于细胞间信号传导。基于MSC衍生EVs的治疗正开始被探索作为基于MSC移植疗法的替代方案。然而,何种MSC来源产生具有最大治疗潜力的EVs仍有待确定。本综述比较了从成人MSC的两种最常见临床来源(骨髓和脂肪组织)分离的EVs的组织再生能力,特别关注它们的血管生成、成骨和免疫调节潜力。还讨论了基于MSC衍生EVs疗法开发中的其他重要问题。